Patents by Inventor Xianming Jin

Xianming Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LpxC INHIBITORS
    Publication number: 20160166548
    Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicant: Novartis AG
    Inventors: Jiping FU, Xianming JIN, Subramanian KARUR, Guillaume LAPOINTE, Ann Marie MADERA, Zachary Kevin SWEENEY
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20160122324
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 5, 2016
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20160120866
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 5, 2016
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 9314464
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: April 19, 2016
    Assignee: Novartis AG
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Aminoheteroaryl benzamides as kinase inhibitors
    Patent number: 9242996
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: January 26, 2016
    Assignee: Novartis AG
    Inventors: Jeffrey T. Bagdanoff, Yu Ding, Wooseok Han, Zilin Huang, Qun Jiang, Jeff Xianming Jin, Xiang Kou, Patrick Lee, Mika Lindvall, Zhongcheng Min, Yue Pan, Sabina Pecchi, Keith Bruce Pfister, Daniel Poon, Vivek Rauniyar, Xiaojing Michael Wang, Qiong Zhang, Jianguang Zhou, Shejin Zhu
  • AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS
    Publication number: 20150126490
    Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 7, 2015
    Applicant: Novartis AG
    Inventors: Jeffrey T. BAGDANOFF, Yu DING, Wooseok HAN, Zilin HUANG, Qun JIANG, Jeff Xianming JIN, Xiang KOU, Patrick LEE, Mika LINDVALL, Zhongcheng MIN, Yue PAN, Sabina PECCHI, Keith Bruce PFISTER, Daniel POON, Vivek RAUNIYAR, Xiaojing Michael WANG, Qiong ZHANG, Jianguang ZHOU, Shejin ZHU
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8859548
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew, Qiong Zhang
  • Compounds and Compositions as Protein Kinase Inhibitors
    Publication number: 20140011825
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Application
    Filed: September 10, 2013
    Publication date: January 9, 2014
    Applicants: NOVARTIS AG, IRM LLC
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
  • 3-(AMINOARYL)-PYRIDINE COMPOUNDS
    Publication number: 20130324530
    Abstract: The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.
    Type: Application
    Filed: November 17, 2011
    Publication date: December 5, 2013
    Inventors: William R. Antonios-McCrea, Paul A. Barsanti, Cheng Hu, Xianming Jin, Eric J. Martin, Yue Pan, Keith B. Pfister, Martin Sendzik, James Sutton, Lifeng Wan
  • SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES
    Publication number: 20130303507
    Abstract: The present invention provides a compound of formula (II): where R1 is a substituted alkyl, heterocyclic, or cycloalkyl, group, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, and pharmaceutical compositions comprising these compounds. Also provided are methods of using these compounds to treat a disease or condition mediated by CDK9, such as cancers and other conditions described herein.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 14, 2013
    Applicant: Novartis AG
    Inventors: William R. Antonios-McCrea, Paul A. Barsanti, Cheng Hu, Xianming Jin, Eric Martin, Yue Pan, Xiaodong Lin, Keith B. Pfister, Paul A. Renhowe, Martin Sendzik, James Sutton, Lifeng Wan
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20130296318
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: June 28, 2013
    Publication date: November 7, 2013
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8563553
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 22, 2013
    Assignees: Novartis AG, IRM LLC
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8501758
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: August 6, 2013
    Assignees: IRM LLC, Novartis AG
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Compounds and Compositions as Protein Kinase Inhibitors
    Publication number: 20120225899
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Application
    Filed: May 16, 2012
    Publication date: September 6, 2012
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff (Xianming) Jin, Zhuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew, Qiong Zhang
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8242260
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew, Qiong Zhang
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20110306625
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: August 27, 2010
    Publication date: December 15, 2011
    Applicants: NOVARTIS AG, IRM LLC
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • Heteroaryl Kinase Inhibitors
    Publication number: 20110130380
    Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.
    Type: Application
    Filed: September 2, 2010
    Publication date: June 2, 2011
    Inventors: Paul A. Barsanti, Cheng Hu, Xianming Jin, Simon C. Ng, Keith B. Pfister, Martin Sendzik, James Sutton
  • Compounds and Compositions as Protein Kinase Inhibitors
    Publication number: 20110052578
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Application
    Filed: August 24, 2010
    Publication date: March 3, 2011
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff (Xianming) Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
  • Chroman derivatives
    Patent number: 7514461
    Abstract: The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: April 7, 2009
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Bing Wang, Gail Walkinshaw, Sekhar Boddupalli, Arkadij M. Elizarov, Xianming Jin, Xianfeng Li, Donald R. James, Jiangao Song, Jian Chen, Wei Zhang
  • 7,8-bicycloalkyl-chroman derivatives
    Patent number: 7470798
    Abstract: 7,8-Bicyclic-chroman derivatives of Formula I: wherein the substituents are defined as in the specification or the pharmaceutically acceptable salts thereof, are disclosed. They are useful for the treatment of inflammatory disorders, neurodegenerative disorders and/or mitochondrial disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: December 30, 2008
    Assignee: Edison Pharmaceuticals, Inc.
    Inventors: Bing Wang, Gail Walkinshaw, Jian Chen, Xianming Jin, Jiangao Song, Wei Zhang